Amlodipine/Valsartan [Design Issues]

posted by Kumarnaidu2 – India, 2023-12-06 10:36 (81 d 05:10 ago) – Posting: # 23781
Views: 668

Dear All,

For the product like Valsartan + Amlodipine or Telmisartan + Amlodipine, is it possible to plan a analysis with 3 way design for Valsartan/Telmisartan and 2 way design for Amlodipine in same study.
For e.g. if we plan a 3 way Partial replicate in 48 subjects (RTR/TRR/RRT). For Val/Telm, sample size will be 48 (All three period) and for Amlodipine, sample size will be 32 (First two period and with sequence RTR and TRR only). Is there any statistical issues with such design?
I know the ideal way is to analyse both Val and Aml in same way.

Complete thread:

UA Flag
Activity
 Admin contact
22,911 posts in 4,806 threads, 1,635 registered users;
30 visitors (1 registered, 29 guests [including 7 identified bots]).
Forum time: 15:46 CET (Europe/Vienna)

The history of statistics is like a telephone directory:
the plot is boring, full of numbers and the cast is endless.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5